ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

ClinicalTrials.gov ID: NCT05489614

Public ClinicalTrials.gov record NCT05489614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal Impairment

Study identification

NCT ID
NCT05489614
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Amgen
Industry
Enrollment
33 participants

Conditions and interventions

Interventions

  • Olpasiran Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 12, 2022
Primary completion
Oct 23, 2023
Completion
Dec 18, 2023
Last update posted
Nov 25, 2025

2022 – 2023

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
Inland Empire Clinical Trials, LLC Rialto California 92377-4697
CRSCA HC LLC, dba Creekside Post Acute Yucaipa California 92399
Clinical Pharmacology Of Miami, LLC Miami Florida 33014
Advanced Pharma CR, LLC Miami Florida 33147-4040
Orlando Clinical Research Center Orlando Florida 32809
Nucleus Network - Minneapolis Saint Paul Minnesota 55114

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05489614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 25, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05489614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →